Constant Therapeutics
BioTech/Drugs - Boston, MA, US
Constant Therapeutics Employees
Constant Therapeutics Senior Management
Constant Therapeutics Details
Constant's lead drug candidate, TXA127, is a pharmaceutical formulation of the natural human peptide, angiotensin-(1-7) [Ang-(1-7)].COVID-19 Program: TXA127 is uniquely positioned at the intersection of two current views of COVID-19:1. The disease is characterized by a diffuse vasculopathy and2. The disease is an ACE2/Ang-(1-7) deficiency.TXA127's mechanism of action addresses much of the pathophysiology of COVID-19 by replacing the lost Ang-(1-7) caused by SARS-CoV-2 binding to ACE2. Recent data shows that the level of Ang-(1-7) is inversely correlated with the severity of COVID-19 disease (Henry, et al. 2020)Ang-(1-7), the active ingredient in Constant's product, TXA127, has been shown to have multiple biologic effects that are relevant to the treatment of COVID-19. These effects include:-reducing oxidative stress and ROS,-restoring the integrity of epithelial and endothelial surfaces,-reducing inflammation by reversing the increased permeability of the blood vessels caused by the virus; thereby preventing movement of inflammatory cells into tissue leading to the "cytokine storm,"-reducing apoptosis,-inhibiting coagulopathy, and-reducing fibrosis through down-regulation of the TGF beta pathway.Ang-(1-7) has been shown to have positive outcomes in a number of animal models of lung injury, stroke and heart disease. In addition, in several disease models it has become clear that blocking the effect of Ang-(1-7) is detrimental.Constant is involved with 3 investigator-initiated clinical trials: at Columbia University Irving Medical Center in NYC; one sponsored by Bar-Ilan University in Israel using sites at Rambam Health Care Campus in Haifa, Ziv Medical Center in Safed and other medical centers in Galilee; and one other US study at sites to be determined. Combined the 3 studies will recruit over 600 patients, with all studies designed as randomized, placebo-controlled trials. The Columbia and Israel studies are currently recruiting.
Constant Therapeutics Technologies
Email Providers
Outlook
CMS
WordPress.org
Other
Mobile Friendly
CSS and JavaScript Libraries
Bootstrap Framework
Analytics and Tracking
Google Analytics